Please login to the form below

Not currently logged in
Email:
Password:

Viela Bio

This page shows the latest Viela Bio news and features for those working in and with pharma, biotech and healthcare.

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

Viela's portfolio of assets includes FDA-approved NMOSD therapy Uplizna. Horizon Therapeutics has entered into a definitive agreement to acquire Viela Bio for $3bn, in an effort to strengthen its ... Viela Bio spun out of AstraZeneca’s Medimmune

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....